ClinicalTrials.gg
Not yet recruitingNCT07001514Updated Jun 3, 2025

Evening Screen Content and Sleep Architecture in Older Adults: Crossover RCT

An interventional study of Calming digital content and Exciting Digital Content in Sleep, sponsored by Blekinge Institute of Technology. Not yet recruiting at 1 site in Sweden. Open to participants aged 60 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Blekinge Institute of Technology · Not applicable, Interventional, and Screening

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
All
01

Study summary

Title

The Effect of Evening Technology Use with Calming vs. Exciting Content on Sleep Architecture in Older Adults: A Crossover Randomized Controlled Trial

Background

The study explores how evening use of digital devices with different types of content (calming vs. exciting) affects sleep in older adults. While technology's effects on sleep have been studied in younger populations, its specific impacts on older adults remain under-researched. This study fills that gap by focusing on subjective and objective sleep measures.

Objectives and Research Questions

Objective: Compare the effects of calming digital content, exciting digital content, and non-digital activities on sleep architecture.

Key Questions:

How does content type impact sleep architecture and quality? Does calming content lead to better sleep outcomes than exciting content? Are there subjective differences in sleep quality across conditions?

Read the detailed description

This study will compare the effects of watching calming (nature documentaries), playing exciting digital games like Ruzzle, and reading a physical book on older adults' subjective and objective sleep quality. This will be a randomized crossover trial. The investigators will exclude participants with diagnosed sleep disorders, Severe cognitive impairment, Use of sleep-affecting medications such as melatonin or benzodiazepines, or Irregular sleep schedules. A sample size of approximately 50 participants (49-51) will be recruited.

All the participants will have all three intervention periods with washout periods in between. During every intervention week, participants will fill out a quick nightly log about their sleep and what tech they used (smartphone, tablet, or a laptop/computer). During sleep, they will wear a comfy EEG headband measuring their sleep stages.

Because everyone eventually does all three conditions, the investigators can compare each person's own results and get more precise answers with fewer people.

The investigators will analyze the data and perform a statistical analysis. The study will be reported in the manuscript and published in a reputable journal.

02

Conditions studied

  • Sleep
03

In context

Lead sponsor

Blekinge Institute of Technology is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 60 - 75 years
  2. Regular evening use of digital devices (e.g., smartphones or tablets)
  3. Willing and able to wear an EEG headband for sleep monitoring throughout the intervention

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed sleep disorder
  2. Severe cognitive impairment
  3. Current use of medications that significantly influence sleep (e.g., melatonin, benzodiazepines)
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Calming Digital Content

    Participants will watch calming digital content - specifically, nature documentaries narrated by Sir David Attenborough - for 30 to 60 minutes within one hour before bedtime. Sleep outcomes will be assessed using EEG recordings and subjective sleep quality logs.

    Behavioral: Calming digital content

  • Experimental
    Exciting Digital Content

    Participants will engage with exciting digital content by playing the word-based game Ruzzle for 30 to 60 minutes within one hour before bedtime. Sleep outcomes will be evaluated using EEG measurements and subjective sleep assessments.

    Behavioral: Exciting Digital Content

  • Active comparator
    Non-Digital Pre-Sleep Activity

    Participants will engage in a non-digital activity by reading a physical, non-fiction book of their choice for 30 to 60 minutes within one hour before bedtime. No digital screens will be used. Sleep outcomes will be monitored via EEG data and self-reported sleep quality measures.

    Behavioral: Non-digital book reading

Interventions

  • BehavioralCalming digital content

    Participants watch a curated selection of soothing documentaries narrated by Sir David Attenborough for 30-60 minutes each evening during one hour before bedtime.

    Also known as: digital, nature documentary

  • BehavioralExciting Digital Content

    Participants engage with the interactive word-based game Ruzzle for 30-60 minutes each evening during one hour before bedtime, designed to provide mental stimulation.

    Also known as: Digital, Ruzzle, Game

  • BehavioralNon-digital book reading

    Participants read a non-fiction book of their choice for the same duration, avoiding all digital screens during one hour before bedtime before bedtime.

    Also known as: book reading

06

What researchers measure

Primary outcomes

  1. Sleep architecture REM

    Sleep architecture containing sleep stages REM - Random eye movement stage.

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

  2. Sleep architecture Deep Sleep

    Sleep architecture containing sleep stages, Deep sleep

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

  3. Sleep architecture, light sleep

    Sleep architecture containing sleep stages, light sleep

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

  4. Sleep latency (time to fall asleep)

    time to fall asleep- through EEG headband

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

  5. Total sleep time (TST)

    Total amount or duration of sleep

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

  6. Sleep efficiency (SE)

    Sleep efficiency (SE)- Sleep efficiency is the percentage of time in bed actually spent sleeping. It is calculated by dividing total sleep time by total time spent in bed and multiplying by 100. Higher sleep efficiency suggests less wakefulness during the night and better overall sleep quality.

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

  7. Wake up after sleep onset (WASO).

    Wake up after sleep onset (WASO).WASO measures the cumulative amount of time a participant spends awake after initially falling asleep, until final morning awakening. Elevated WASO values may indicate fragmented or disrupted sleep, which can negatively affect sleep quality and daytime functioning.

    Time frame: Nightly during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant.

Secondary outcomes

  1. Subjective sleep quality

    Single-Item Sleep Quality Scale. Range 0 (Terrible) to 10 (Excellent)

    Time frame: Each morning from Day 1 through Day 35 after each participant's enrollment, covering all intervention and washout weeks; up to 5 weeks per participant

  2. Comfort of using the EEG headband

    How comfortable do you find wearing the EEG headband at night? 1. - Very uncomfortable 2. - Slightly uncomfortable 3. - Neither comfortable nor uncomfortable 4. - Somewhat comfortable 5. - Very comfortable

    Time frame: Each morning during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant

  3. Intervention Adherence

    Participants will be asked whether they were able to complete the assigned evening activity the previous night. If the answer is "yes," they will also report how long they engaged in the intervention (in minutes). This self-report measure will help evaluate the feasibility and real-world compliance with each intervention condition.

    Time frame: Each morning during each participant's 7-day intervention periods - Week 1 (Days 1-7), Week 3 (Days 15-21), and Week 5 (Days 29-35) after that participant's enrollment; up to 5 weeks per participant

Other outcomes

  1. Baseline survey

    Before the first intervention phase, participants complete a baseline survey assessing: Sociodemographic characteristics (Gender, Living status, economic situation, working status, how many hours do you work, education status). Subjective sleep health (SATED 3 item likert scale instrument with five questions). Sleeping habits (sleep medication use?, Sleep-schedule regularity,Daytime napping, Evening screen exposure, Sleep disruption by physical symptoms (pain,itching), Sleep disruption by psychological factors, Night-time technology use, Nocturia). Chronotype (The reduced Morningness-Eveningness Questionnaire), general health status (0 bad to 4 excellent). Technology use (On average, how often have you used the INTERNET on your computer, tablet and smartphone in the last three months?).

    Time frame: Baseline (Day 0, at enrollment; one-time survey)

07

Study locations

1 site
  • Blekinge Institute of Technology
    Karlskrona, Blekinge SE-371 79, Sweden
    • Johan Sanmartin Berglund · Contactjohan.sanmartin.berglund@bth.se · +46 (0) 455-385471
    • Sarah Nauman Ghazi · Sub investigator
    • Anders Behrens · Sub investigator
    • Joakim Niklasson · Sub investigator
    • Jessica Berner · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual Participant Data (IPD) will not be shared publicly because the study involves sensitive sleep and health-related data from older adult participants. To protect participant privacy and confidentiality, the data will remain anonymized and securely stored for analysis by the research team only. Public sharing of individual-level data is not planned.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for May 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
Jun 3, 2025
StartEst.
Aug 2025
Primary completionEst.
May 2026
CompletionEst.
Dec 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07001514
Lead sponsor
Blekinge Institute of Technology
Responsible party
Sponsor
First posted
Jun 3, 2025
Start date
Aug 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 3, 2025

Study contacts

Peter Anderberg, PhD
Contact
peter.anderberg@bth.se
+46734223736
Sarah Nauman Ghazi, MD| M.Sc. | Fil. Licentiate
Contact
sarah.n.ghazi@bth.se
+46706604935
Peter Anderberg, PhD
principal investigator · Blekinge Institute of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion